Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
COYA
$4.9
$
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an allogeneic Treg exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.
Next Earnings
2026-02-25
Beta
0.271
Average Volume
Market Cap
Last Dividend
CIK
0001835022
ISIN
US22407B1089
CUSIP
CEO
Arun Swaminathan
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
8
IPO Date
2022-12-29
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Coya Therapeutics Details ALS Combo Immunotherapy Plan, Highlights Early Biomarker Signals in Webinar | Speakers on a Coya Therapeutics (NASDAQ: COYA) webinar outlined the company's scientific rationale and clinical development plans for an investigational combination immunotherapy in amyotrophic lateral sclerosis (ALS), emphasizing a shift in the field toward more targeted, biology-driven approaches. ALS landscape and the push for targeted biology During the discussion, presenters described an "huge need" for therapies | Defense World | 2026-02-19 04:07:03 |
| Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial | HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorder, today announced it will host a live webinar on February 17, 2026 at 3:00 p.m. ET/ 12:00 p.m. PT exploring the evolving ALS treatment landscape. Titled ‘Inside the Evolving ALS Landscape: Biology, Innovation, and Clinical Progress', the webinar will explore re. | Business Wire | 2026-02-10 08:00:00 |
| Coya Therapeutics Announces $11.1 Million Private Placement | HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announced today that it has entered into a definitive securities purchase agreement for the purchase and sale of an aggregate of 2,522,727 shares of its common stock in a private placement at a price of $4.40 per share. The offering is expecte. | Business Wire | 2026-01-30 08:00:00 |
| Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders | HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, releases the following letter to stockholders from Chief Executive Officer Dr. Arun Swaminathan. Dear Fellow Stockholders, Coya enters 2026 with strong momentum and a clear sense of purpose. I believe we are exceptionally well positioned to advance our mission of delivering potentially transformational therapie. | Business Wire | 2026-01-20 08:00:00 |
| Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients | HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, today announced positive results of an investigator-initiated proof of concept open-label study with low-dose IL-2 and CTLA4-Ig combination treatment in 9 patients with Frontotemporal Dementia (FTD) over a 6 month period. The study was led by. | Business Wire | 2026-01-08 08:00:00 |
| Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD) | HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces that the U.S. Food and Drug Administration (FDA) has accepted the Company's IND for COYA 302 for the treatment of frontotemporal dementia (FTD). FTD is the most common form of dementia in people under the age of 65, affecting about 6. | Business Wire | 2026-01-05 08:00:00 |
| Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS) | HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces that Health Canada has accepted, without objection, the Clinical Trial Application (CTA) for COYA 302 for the treatment of amyotrophic lateral sclerosis (ALS). The CTA acceptance by Health Canada allows for activation of clinical sit. | Business Wire | 2025-12-23 08:00:00 |
| Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS | HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announced that dosing of ALS patients in the Company's ALSTARS Trial of COYA 302 has commenced. Dr. Fred Grossman, the Company's Chief Medical Officer, said, “We are very pleased that the ALSTARS Trial is underway, and we want to extend our si. | Business Wire | 2025-12-09 08:00:00 |
| Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences | HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces the company's management team will participate in two upcoming conferences. 8th Annual Evercore Healthcare Conference Date: December 2, 2025 Time: 8:45-9:05 am ET Format: Fireside Chat Participant: Dr. Arun Swaminathan, Ph.D., Chief. | Business Wire | 2025-11-25 08:00:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| SC 13G/A | 2026-01-30 | 2026-01-30 | View Filing |
| 8-K | 2026-01-30 | 2026-01-30 | View Filing |
| SC 13G/A | 2026-01-28 | 2026-01-28 | View Filing |
| 4 | 2026-01-26 | 2026-01-26 | View Filing |
| 4 | 2026-01-26 | 2026-01-26 | View Filing |
| 4 | 2026-01-26 | 2026-01-26 | View Filing |
| 4 | 2026-01-26 | 2026-01-26 | View Filing |
| 8-K | 2026-01-20 | 2026-01-20 | View Filing |
| 8-K | 2026-01-08 | 2026-01-08 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 8-K | 2025-12-17 | 2025-12-17 | View Filing |
| 10-Q | 2025-11-12 | 2025-11-12 | View Filing |
| 8-K | 2025-11-12 | 2025-11-12 | View Filing |
| 8-K | 2025-10-27 | 2025-10-27 | View Filing |
| 424B5 | 2025-10-27 | 2025-10-27 | View Filing |
| 424B5 | 2025-10-23 | 2025-10-23 | View Filing |
| 8-K | 2025-09-02 | 2025-09-02 | View Filing |
| EFFECT | 2025-08-20 | 2025-08-20 | View Filing |
| 424B7 | 2025-08-19 | 2025-08-19 | View Filing |
| 4 | 2025-08-19 | 2025-08-19 | View Filing |
| S-3 | 2025-08-12 | 2025-08-12 | View Filing |
| 10-Q | 2025-08-12 | 2025-08-12 | View Filing |
| 8-K | 2025-08-12 | 2025-08-12 | View Filing |
| 8-K | 2025-07-29 | 2025-07-29 | View Filing |
| 8-K | 2025-07-01 | 2025-07-01 | View Filing |
| 8-K | 2025-06-26 | 2025-06-26 | View Filing |
| ARS | 2025-05-16 | 2025-05-16 | View Filing |
| DEFA14A | 2025-05-16 | 2025-05-16 | View Filing |
| DEF 14A | 2025-05-16 | 2025-05-16 | View Filing |
| 10-Q | 2025-05-13 | 2025-05-13 | View Filing |
| 8-K | 2025-05-13 | 2025-05-13 | View Filing |
| 10-K/A | 2025-04-28 | 2025-04-28 | View Filing |
| 10-K | 2025-03-18 | 2025-03-18 | View Filing |
| 8-K | 2025-03-18 | 2025-03-18 | View Filing |
| 4 | 2025-02-25 | 2025-02-25 | View Filing |
| 4 | 2025-02-25 | 2025-02-25 | View Filing |
| 4 | 2025-02-25 | 2025-02-25 | View Filing |
| 4 | 2025-02-25 | 2025-02-25 | View Filing |
| 4 | 2025-02-25 | 2025-02-25 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| SC 13G/A | 2025-02-10 | 2025-02-10 | View Filing |
| S-8 | 2025-01-30 | 2025-01-30 | View Filing |
| 4 | 2025-01-13 | 2025-01-13 | View Filing |
| 4 | 2025-01-13 | 2025-01-13 | View Filing |
| 4 | 2025-01-13 | 2025-01-13 | View Filing |
| 4 | 2025-01-13 | 2025-01-13 | View Filing |
| 4 | 2025-01-03 | 2025-01-03 | View Filing |
| 4 | 2025-01-03 | 2025-01-03 | View Filing |
| 4 | 2025-01-03 | 2025-01-03 | View Filing |
| 4 | 2025-01-03 | 2025-01-03 | View Filing |
| 4 | 2025-01-03 | 2025-01-03 | View Filing |
| EFFECT | 2024-12-02 | 2024-12-02 | View Filing |
| 424B3 | 2024-11-29 | 2024-11-29 | View Filing |
| S-3 | 2024-11-20 | 2024-11-20 | View Filing |
| 4 | 2024-11-14 | 2024-11-14 | View Filing |
| 4 | 2024-11-13 | 2024-11-13 | View Filing |
| 4 | 2024-11-12 | 2024-11-12 | View Filing |
| 4 | 2024-11-12 | 2024-11-12 | View Filing |
| SC 13G/A | 2024-11-12 | 2024-11-12 | View Filing |
| 10-Q | 2024-11-06 | 2024-11-06 | View Filing |
| 8-K | 2024-11-06 | 2024-11-06 | View Filing |
| 8-K | 2024-11-05 | 2024-11-05 | View Filing |
| SC 13G/A | 2024-11-04 | 2024-11-04 | View Filing |
| SC 13G/A | 2024-11-04 | 2024-11-04 | View Filing |
| 8-K | 2024-10-31 | 2024-10-31 | View Filing |
| 8-K | 2024-10-29 | 2024-10-29 | View Filing |
| D | 2024-10-28 | 2024-10-28 | View Filing |
| 8-K | 2024-10-22 | 2024-10-22 | View Filing |
| 3 | 2024-08-20 | 2024-08-20 | View Filing |
| 8-K | 2024-08-19 | 2024-08-19 | View Filing |
| 10-Q | 2024-08-12 | 2024-08-12 | View Filing |
| 8-K | 2024-08-12 | 2024-08-12 | View Filing |
| 8-K | 2024-07-15 | 2024-07-15 | View Filing |
| 424B3 | 2024-06-24 | 2024-06-24 | View Filing |
| EFFECT | 2024-06-24 | 2024-06-24 | View Filing |
| S-3 | 2024-06-14 | 2024-06-14 | View Filing |
| 4 | 2024-06-05 | 2024-06-05 | View Filing |
| 4 | 2024-06-05 | 2024-06-05 | View Filing |
| 4 | 2024-06-05 | 2024-06-05 | View Filing |
| 8-K | 2024-06-05 | 2024-06-05 | View Filing |
| 8-K | 2024-05-20 | 2024-05-20 | View Filing |
| 10-Q | 2024-05-09 | 2024-05-09 | View Filing |
| 8-K | 2024-05-09 | 2024-05-09 | View Filing |
| 8-K | 2024-05-08 | 2024-05-08 | View Filing |
| DEFA14A | 2024-03-29 | 2024-03-28 | View Filing |
| ARS | 2024-03-28 | 2024-03-28 | View Filing |
| DEFA14A | 2024-03-28 | 2024-03-28 | View Filing |
| DEF 14A | 2024-03-28 | 2024-03-28 | View Filing |
| 10-K | 2024-03-19 | 2024-03-19 | View Filing |
| 8-K | 2024-03-19 | 2024-03-19 | View Filing |
| 4 | 2024-03-05 | 2024-03-05 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Larry Williams PercentR Strategy | 59.38% | 0.99 | 165 | 0.04 | 0.09 | 50.58 |
| Neural Forcast | 36.92% | 1 | 687 | 0.03 | 0.07 | 28.12 |
| Mean Reversion Strategy | 29.38% | 1 | 395 | 0.04 | 0.1 | 20.58 |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | x | xxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | x |
| xxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | x | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xxx | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | x | xxxxx |
| xxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |